We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Kimberly Lewandowski-Walker
Kimberly Lewandowski-Walker
Products
PRODUCTS
Align Spine LLC
Kimberly Lewandowski-Walker
Price:
$117.00
View
Rockford Specialties
Kimberly Lewandowski-Walker
Price:
$117.00
View
Alma Lasers, Inc.
Kimberly Lewandowski-Walker
Price:
$117.00
View
Stericycle
Kimberly Lewandowski-Walker
Price:
$117.00
View
Healthtronics, Inc.
Kimberly Lewandowski-Walker
and
Iris C. Macinnes
Price:
$117.00
View
Beta Biomed Services, Inc.
Casey Hamblin
and
Kimberly Lewandowski-Walker
Price:
$117.00
View
Sirtex Singapore Manufacturing Pte. Ltd.
Kimberly Lewandowski-Walker
Price:
$117.00
View
MP Biomedicals Asia Pacific Ptd. Ltd.
Pradip Akolkar
and
Kimberly Lewandowski-Walker
Price:
$117.00
View
7 Mile Solutions, Inc., dba Maxant Technologies
Kimberly Lewandowski-Walker
Price:
$117.00
View
Ciba Vision Corp.
Kimberly Lewandowski-Walker
and
Jesse A. Vazquez
Price:
$117.00
View
View All Products by Kimberly Lewandowski-Walker
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More